Unicycive Therapeutics Inc (UNCY) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket
 


Unicycive Therapeutics Inc  (NASDAQ: UNCY)


Unicycive Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Unicycive Therapeutics Inc's ROI in the second quarter of 2026?
Unicycive Therapeutics Inc recorded a cumulative net loss of $-35 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -68.73%.

Within the Healthcare sector 486 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3944 to 4355.

Definition and Formula of Return on Investment



Return On Investment (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 2575.09 % 635.68 % 253.77 % 265.31 % -85.81 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 53 60 45 47 16
Return On Investment (TTM) -68.73 % -95.06 % -89.35 % -134.15 % -1338.01 %
UNCY's Overall Ranking # 4355 # 3944 # 3478 # #
Seq. Investment Change TTM 21.95 % 41.08 % 45.06 % 971.9 % -66.46 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -35 -40 -27 -28 -26




Return On Investment UNCY's Ranking
Within: No.
Industry # 212
Sector # 487
Overall # 4355

Return On Investment Statistics
High Average Low
-68.73 %
-238.18 %
-643.37 %
(Jun 30 2026)   (Dec 31 2023)







Financial Statements
Unicycive Therapeutics Inc's II. Quarter Investments $ 53 Millions UNCY's Balance sheet
Unicycive Therapeutics Inc's II. Quarter Income $ -2 Millions Quarterly UNCY's Income Statement
UNCY's Income by Division See UNCY's Income by Division


UNCY Annual Return On Investment (Dec 31 2025)
2025
(Dec 31 2024)
2024
(Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
Total Investments in Millions 30 8 -4 0 17
Y / Y Investment Growth 300.44 % - - - -
Net Income in Millions -27 -37 -31 -18 -10
Y / Y Net Income Growth - - - - -
Annual Return On Investment -87.86 % -486.61 % - - -60.2 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
UNCY's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for UNCY's Competitors
Subscribers only: Roi for Unicycive Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for UNCY's Customers

Other Ratios
UNCY's Roa UNCY's Inventory Turnover Ratio UNCY's Growth Rates UNCY's Dividend Statistics
UNCY's Profitability Ratios UNCY's Asset Turnover Ratio UNCY's Dividend Growth
UNCY's Roe UNCY's Valuation Ratios UNCY's Financial Strength Ratios UNCY's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI


Date modified: 2026-09-26T07:40:21+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.